NI
ENGN icon

Nextech Invest’s enGene Therapeutics ENGN Stock Holding History

Nextech Invest’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.02M Hold
2,324,943
– – 0.19% 15
2026
Q1 		$15.8M Buy
2,324,943
+200,000
+9% +$1.78M 1.11% 12
2025
Q4 		$19.2M Buy
+2,124,943
New +$17M 1.86% 9

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Nextech Invest's ENGN Position: Q2 2026 in Review

Nextech Invest held its enGene Therapeutics (ENGN) position steady in Q2 2026 at 2,324,943 shares worth $4.02M. The position accounts for 0.19% of the portfolio, ranked #15.

Nextech Invest first reported a position in ENGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $19.2M in Q4 2025. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • Nextech Invest held 2,324,943 shares of enGene Therapeutics worth $4.02M as of Q2 2026.
  • Nextech Invest left its enGene Therapeutics share count unchanged in Q2 2026.
  • enGene Therapeutics made up 0.19% of Nextech Invest's portfolio in Q2 2026, its #15 holding.
  • Nextech Invest first reported a position in enGene Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Nextech Invest's enGene Therapeutics position peaked at $19.2M in Q4 2025.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Nextech Invest's 13F filing for Q2 2026, filed 14 Aug 2026.